Weighing the evidence: Variant classification and interpretation in precision oncology, US food and drug administration public workshop-Workshop proceedings

Hisani N. Horne, Donna Roscoe, E. David Litwack, Anand Pathak, Jai P. Pandey, Pamela S. Gallagher, Laura M. Koontz, Robert N. Schuck, Eunice Y. Lee, Yun Fu Hu, Julia A. Beaver, Gideon M. Blumenthal, Reena Philip

Research output: Contribution to journalArticle

Abstract

PURPOSE Next-generation sequencing (NGS) oncology panels are becoming integral in hospital and academic settings to guide patient treatment and enrollment in clinical trials. Although NGS technologies have revolutionized decision-making for cancer therapeutics, physicians may face many challenges in parsing and prioritizing NGS-based test results to determine the best course of treatment for individual patients. On January 29, 2018, the US Food and Drug Administration held a public workshop entitled, "Weighing the Evidence: Variant Classification and Interpretation in Precision Oncology." Here, we discuss the presentations and discussion highlights across the four sessions of the workshop. METHODS The goal of the public workshop was to engage stakeholders and solicit input from experts in precision oncology to discuss the integration of complex NGS data into patient management and regulatory innovation within the precision oncology community. The US Food and Drug Administration gathered representatives from academia, industry, patient advocacy, government, and professional organizations for a series of presentations followed by panel discussions. After the workshop, the transcript and speaker presentation slides were reviewed and summarized for manuscript preparation. RESULTS Speakers and panelists provided diverse perspectives on the integration of NGS technology into patient care for oncology and on the complexities that surround data interpretation and sharing. Discussions highlighted the challenges with standardization for variant classification while expressing the utility of consensus recommendations among stakeholders in oncology for driving innovation in the era of precision medicine. CONCLUSION As precision medicine advances, clear communication within the field of precision oncology will be key to creating an environment that facilitates the generation and sharing of data that have value to patients.

Original languageEnglish (US)
JournalJCO Precision Oncology
Volume3
DOIs
StatePublished - Jan 1 2019

Fingerprint

United States Food and Drug Administration
Education
Precision Medicine
Information Dissemination
Technology
Patient Advocacy
Manuscripts
Consensus
Decision Making
Patient Care
Industry
Therapeutics
Communication
Clinical Trials
Physicians
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Weighing the evidence : Variant classification and interpretation in precision oncology, US food and drug administration public workshop-Workshop proceedings. / Horne, Hisani N.; Roscoe, Donna; David Litwack, E.; Pathak, Anand; Pandey, Jai P.; Gallagher, Pamela S.; Koontz, Laura M.; Schuck, Robert N.; Lee, Eunice Y.; Hu, Yun Fu; Beaver, Julia A.; Blumenthal, Gideon M.; Philip, Reena.

In: JCO Precision Oncology, Vol. 3, 01.01.2019.

Research output: Contribution to journalArticle

Horne, HN, Roscoe, D, David Litwack, E, Pathak, A, Pandey, JP, Gallagher, PS, Koontz, LM, Schuck, RN, Lee, EY, Hu, YF, Beaver, JA, Blumenthal, GM & Philip, R 2019, 'Weighing the evidence: Variant classification and interpretation in precision oncology, US food and drug administration public workshop-Workshop proceedings', JCO Precision Oncology, vol. 3. https://doi.org/10.1200/PO.18.00314
Horne, Hisani N. ; Roscoe, Donna ; David Litwack, E. ; Pathak, Anand ; Pandey, Jai P. ; Gallagher, Pamela S. ; Koontz, Laura M. ; Schuck, Robert N. ; Lee, Eunice Y. ; Hu, Yun Fu ; Beaver, Julia A. ; Blumenthal, Gideon M. ; Philip, Reena. / Weighing the evidence : Variant classification and interpretation in precision oncology, US food and drug administration public workshop-Workshop proceedings. In: JCO Precision Oncology. 2019 ; Vol. 3.
@article{ac6e693bdd0c43d88ed388f4af0a0df9,
title = "Weighing the evidence: Variant classification and interpretation in precision oncology, US food and drug administration public workshop-Workshop proceedings",
abstract = "PURPOSE Next-generation sequencing (NGS) oncology panels are becoming integral in hospital and academic settings to guide patient treatment and enrollment in clinical trials. Although NGS technologies have revolutionized decision-making for cancer therapeutics, physicians may face many challenges in parsing and prioritizing NGS-based test results to determine the best course of treatment for individual patients. On January 29, 2018, the US Food and Drug Administration held a public workshop entitled, {"}Weighing the Evidence: Variant Classification and Interpretation in Precision Oncology.{"} Here, we discuss the presentations and discussion highlights across the four sessions of the workshop. METHODS The goal of the public workshop was to engage stakeholders and solicit input from experts in precision oncology to discuss the integration of complex NGS data into patient management and regulatory innovation within the precision oncology community. The US Food and Drug Administration gathered representatives from academia, industry, patient advocacy, government, and professional organizations for a series of presentations followed by panel discussions. After the workshop, the transcript and speaker presentation slides were reviewed and summarized for manuscript preparation. RESULTS Speakers and panelists provided diverse perspectives on the integration of NGS technology into patient care for oncology and on the complexities that surround data interpretation and sharing. Discussions highlighted the challenges with standardization for variant classification while expressing the utility of consensus recommendations among stakeholders in oncology for driving innovation in the era of precision medicine. CONCLUSION As precision medicine advances, clear communication within the field of precision oncology will be key to creating an environment that facilitates the generation and sharing of data that have value to patients.",
author = "Horne, {Hisani N.} and Donna Roscoe and {David Litwack}, E. and Anand Pathak and Pandey, {Jai P.} and Gallagher, {Pamela S.} and Koontz, {Laura M.} and Schuck, {Robert N.} and Lee, {Eunice Y.} and Hu, {Yun Fu} and Beaver, {Julia A.} and Blumenthal, {Gideon M.} and Reena Philip",
year = "2019",
month = "1",
day = "1",
doi = "10.1200/PO.18.00314",
language = "English (US)",
volume = "3",
journal = "JCO Precision Oncology",
issn = "2473-4284",

}

TY - JOUR

T1 - Weighing the evidence

T2 - Variant classification and interpretation in precision oncology, US food and drug administration public workshop-Workshop proceedings

AU - Horne, Hisani N.

AU - Roscoe, Donna

AU - David Litwack, E.

AU - Pathak, Anand

AU - Pandey, Jai P.

AU - Gallagher, Pamela S.

AU - Koontz, Laura M.

AU - Schuck, Robert N.

AU - Lee, Eunice Y.

AU - Hu, Yun Fu

AU - Beaver, Julia A.

AU - Blumenthal, Gideon M.

AU - Philip, Reena

PY - 2019/1/1

Y1 - 2019/1/1

N2 - PURPOSE Next-generation sequencing (NGS) oncology panels are becoming integral in hospital and academic settings to guide patient treatment and enrollment in clinical trials. Although NGS technologies have revolutionized decision-making for cancer therapeutics, physicians may face many challenges in parsing and prioritizing NGS-based test results to determine the best course of treatment for individual patients. On January 29, 2018, the US Food and Drug Administration held a public workshop entitled, "Weighing the Evidence: Variant Classification and Interpretation in Precision Oncology." Here, we discuss the presentations and discussion highlights across the four sessions of the workshop. METHODS The goal of the public workshop was to engage stakeholders and solicit input from experts in precision oncology to discuss the integration of complex NGS data into patient management and regulatory innovation within the precision oncology community. The US Food and Drug Administration gathered representatives from academia, industry, patient advocacy, government, and professional organizations for a series of presentations followed by panel discussions. After the workshop, the transcript and speaker presentation slides were reviewed and summarized for manuscript preparation. RESULTS Speakers and panelists provided diverse perspectives on the integration of NGS technology into patient care for oncology and on the complexities that surround data interpretation and sharing. Discussions highlighted the challenges with standardization for variant classification while expressing the utility of consensus recommendations among stakeholders in oncology for driving innovation in the era of precision medicine. CONCLUSION As precision medicine advances, clear communication within the field of precision oncology will be key to creating an environment that facilitates the generation and sharing of data that have value to patients.

AB - PURPOSE Next-generation sequencing (NGS) oncology panels are becoming integral in hospital and academic settings to guide patient treatment and enrollment in clinical trials. Although NGS technologies have revolutionized decision-making for cancer therapeutics, physicians may face many challenges in parsing and prioritizing NGS-based test results to determine the best course of treatment for individual patients. On January 29, 2018, the US Food and Drug Administration held a public workshop entitled, "Weighing the Evidence: Variant Classification and Interpretation in Precision Oncology." Here, we discuss the presentations and discussion highlights across the four sessions of the workshop. METHODS The goal of the public workshop was to engage stakeholders and solicit input from experts in precision oncology to discuss the integration of complex NGS data into patient management and regulatory innovation within the precision oncology community. The US Food and Drug Administration gathered representatives from academia, industry, patient advocacy, government, and professional organizations for a series of presentations followed by panel discussions. After the workshop, the transcript and speaker presentation slides were reviewed and summarized for manuscript preparation. RESULTS Speakers and panelists provided diverse perspectives on the integration of NGS technology into patient care for oncology and on the complexities that surround data interpretation and sharing. Discussions highlighted the challenges with standardization for variant classification while expressing the utility of consensus recommendations among stakeholders in oncology for driving innovation in the era of precision medicine. CONCLUSION As precision medicine advances, clear communication within the field of precision oncology will be key to creating an environment that facilitates the generation and sharing of data that have value to patients.

UR - http://www.scopus.com/inward/record.url?scp=85077488125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077488125&partnerID=8YFLogxK

U2 - 10.1200/PO.18.00314

DO - 10.1200/PO.18.00314

M3 - Article

AN - SCOPUS:85077488125

VL - 3

JO - JCO Precision Oncology

JF - JCO Precision Oncology

SN - 2473-4284

ER -